FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX for patients with metastatic pancreatic cancer and appears to be better tolerated with the ability to administer at least 10 cycles of therapy. Investigators therefore will evaluate FOLFOX-A in a phase II study for patient with locally advanced pancreatic cancer.
Locally Advanced Pancreatic Cancer|Pancreatic Cancer
DRUG: FOLFOXA
Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer., From date of start of treatment, until the date of first documented progression, whichever came first, assessed up to 3 years
Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A, During treatment (approximately every 2 weeks for up to 6 months), then approximately every 4 months for for a maximum of 5 years
See summary above